{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:04:25Z","timestamp":1789452265754,"version":"build-2803163510"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Annals of Neurosciences"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Peripheral neuropathy is four times more common in geriatric age group patients compared to younger ones. Most of the trials have targeted adult population, and there is scarcity of data in the geriatric age group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>A real-world study was planned on geriatric patients suffering from peripheral neuropathy to analyse the effectiveness and safety of first-line drugs used in the management of peripheral neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      It was a randomised, open-label, active comparator clinical trial in which first-line drugs for peripheral neuropathy were compared [amitriptyline (10 mg), duloxetine (30 mg), gabapentin (300 mg), pregabalin (75 mg)] for their effectiveness and safety. The trial duration was eight weeks. The modified Toronto Clinical Neuropathy Score (mTCNS), Verbal Rating Scale (VRS) and Geriatric Depression Scale (GDS) were used for effectiveness. Safety was assessed by monitoring adverse events. Multiple groups were compared with Kruskal\u2013Wallis test, and post hoc analysis was performed with Dunn\u2019s test. A\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      value &lt;.05 was considered significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 80 patients were recruited (20 patients in each arm) with a mean age of 65.4 years, and 56.3% were male. Pregabalin was superior to amitriptyline (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .04) and duloxetine (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .02) in reducing mTCNS. Similarly, pregabalin was superior to amitriptyline (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .041 and duloxetine (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .009) in reducing GDS score. All drugs were comparable in reducing VRS (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = .17). A total of 14 adverse events were observed, out of which constipation, sedation and dizziness were common. Maximum adverse events were observed in the duloxetine arm (6\/14).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pregabalin was superior to amitriptyline and duloxetine, whereas it was comparable to gabapentin in effectiveness. Constipation was the most common adverse event, but the central nervous system was the most involved in adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09727531241243126","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T06:28:36Z","timestamp":1716964116000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Effectiveness and Safety of First-line Drugs Used in the Treatment of Peripheral Neuropathy Among Elderly Population\u2014A Randomised, Open-label, Active Comparator Study"],"prefix":"10.1177","volume":"33","author":[{"given":"Mahesh Kumar","family":"Balasundaram","sequence":"first","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Kumar","family":"Kannauje","sequence":"additional","affiliation":[{"name":"Department of General Medicine, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suryaprakash","family":"Dhaneria","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6720-2756","authenticated-orcid":false,"given":"Alok","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"e_1_3_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.10.006"},{"key":"e_1_3_8_3_2","doi-asserted-by":"crossref","unstructured":"Jones LK. Nerve conduction studies: basic concepts and patterns of abnormalities. Neurol Clin 2012 May; 30(2): 405\u2013427. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861911001320.","DOI":"10.1016\/j.ncl.2011.12.002"},{"key":"e_1_3_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12170"},{"key":"e_1_3_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13533"},{"key":"e_1_3_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02667.x"},{"key":"e_1_3_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.05.004"},{"key":"e_1_3_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.04.001"},{"key":"e_1_3_8_9_2","unstructured":"Finnerup NB Attal N Haroutounian S . Pharmacotherapy for neuropathic pain in adults: systematic review meta-analysis and updated NeuPSIG recommendations. Lancet Neurol 2015; 14(2): 162\u2013173. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4493167\/"},{"key":"e_1_3_8_10_2","doi-asserted-by":"crossref","unstructured":"Tripepi G Chesnaye NC Dekker FW . Intention to treat and per protocol analysis in clinical trials. Nephrology 2020; 25(7): 513\u2013517. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/nep.13709","DOI":"10.1111\/nep.13709"},{"key":"e_1_3_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.endmts.2020.100053"},{"key":"e_1_3_8_12_2","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.138750"},{"key":"e_1_3_8_13_2","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.131184"},{"key":"e_1_3_8_14_2","doi-asserted-by":"publisher","DOI":"10.4081\/jphr.2015.450"},{"key":"e_1_3_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12223"},{"key":"e_1_3_8_16_2","doi-asserted-by":"publisher","DOI":"10.4103\/jiag.jiag_23_23"},{"issue":"6","key":"e_1_3_8_17_2","first-page":"504","article-title":"Prevalence of micro and macrovascular complications and their risk factors in type-2 diabetes mellitus","volume":"62","author":"Agrawal RP","year":"2014","unstructured":"Agrawal RP, , Ola V, , Bishnoi P, . Prevalence of micro and macrovascular complications and their risk factors in type-2 diabetes mellitus. J Assoc Physicians India 2014; 62(6): 504\u2013508.","journal-title":"J Assoc Physicians India"},{"key":"e_1_3_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2009.02806.x"},{"key":"e_1_3_8_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0656"},{"key":"e_1_3_8_20_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1793"},{"key":"e_1_3_8_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S185995"},{"key":"e_1_3_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13148"},{"key":"e_1_3_8_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-013-0080-2"},{"key":"e_1_3_8_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/28.2.187"},{"key":"e_1_3_8_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1363-2"},{"key":"e_1_3_8_26_2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7408508"},{"key":"e_1_3_8_27_2","volume-title":"Basic & clinical pharmacology","author":"Katzung BG","year":"2015","unstructured":"Katzung BG, , Masters SB, and Trevor AJ. Basic & clinical pharmacology. New York: McGraw-Hill Medical, 2015."},{"key":"e_1_3_8_28_2","doi-asserted-by":"crossref","unstructured":"Whitehead AL Julious SA Cooper CL . Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res 2016; 25(3): 1057\u20131073. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4876429\/","DOI":"10.1177\/0962280215588241"}],"container-title":["Annals of Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09727531241243126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09727531241243126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09727531241243126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:27Z","timestamp":1789450467000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09727531241243126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/09727531241243126"],"URL":"https:\/\/doi.org\/10.1177\/09727531241243126","relation":{},"ISSN":["0972-7531","0976-3260"],"issn-type":[{"value":"0972-7531","type":"print"},{"value":"0976-3260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}